Table 1.
Median TTTTD and OS times, starting from the initiation of second-line (2L) therapy, overall and in subgroups defined by time on first-line (1L) therapy. Median survival estimates and 95% confidence intervals (CIs) are estimated using the Kaplan–Meier method, and are not adjusted for any covariates. Confidence limits that could not be estimated due to limited sample size are denoted by “-”. TTTTD is time to third-line treatment or death, and OS is overall survival.
| 1L Therapy | Population | Outcome | 2L Therapy | N | Events | Median Survival, Months (95% CI) |
|---|---|---|---|---|---|---|
| Abiraterone | Overall | TTTTD | Enzalutamide | 508 | 422 | 5.9 (5.6, 6.7) |
| Docetaxel | 187 | 161 | 5.1 (4.7, 5.7) | |||
| OS | Enzalutamide | 508 | 352 | 15.6 (12.7, 16.7) | ||
| Docetaxel | 187 | 144 | 8.7 (7.7, 11.6) | |||
| 1L NHT < 6 months | TTTTD | Enzalutamide | 184 | 154 | 5.9 (5.4, 7.1) | |
| Docetaxel | 115 | 104 | 5.0 (4.7, 5.7) | |||
| OS | Enzalutamide | 184 | 128 | 15.1 (11.0, 18.4) | ||
| Docetaxel | 115 | 91 | 9.1 (7.7, 12.1) | |||
| 1L NHT ≥ 6 months | TTTTD | Enzalutamide | 324 | 268 | 6.0 (5.5, 7.0) | |
| Docetaxel | 72 | 57 | 5.5 (4.3, 6.6) | |||
| OS | Enzalutamide | 324 | 224 | 15.6 (12.8, 16.7) | ||
| Docetaxel | 72 | 53 | 8.4 (6.3, 13.2) | |||
| 1L NHT < 12 months | TTTTD | Enzalutamide | 362 | 306 | 5.6 (5.3, 6.4) | |
| Docetaxel | 164 | 148 | 5.0 (4.6, 5.5) | |||
| OS | Enzalutamide | 362 | 263 | 12.5 (10.9, 15.6) | ||
| Docetaxel | 164 | 132 | 8.1 (7.3, 10.3) | |||
| 1L NHT ≥ 12 months | TTTTD | Enzalutamide | 146 | 116 | 8.2 (5.9, 10.1) | |
| Docetaxel | 23 | 13 | 8.5 (4.7, -) | |||
| OS | Enzalutamide | 146 | 89 | 18.9 (16.5, 24.6) | ||
| Docetaxel | 23 | 12 | 16.0 (12.4, -) | |||
| Enzalutamide | Overall | TTTTD | Abiraterone | 290 | 226 | 6.3 (5.5, 7.0) |
| Docetaxel | 132 | 117 | 4.7 (4.4, 5.4) | |||
| OS | Abiraterone | 290 | 182 | 13.2 (11.4, 15.0) | ||
| Docetaxel | 132 | 103 | 9.7 (8.6, 12.6) | |||
| 1L NHT < 6 months | TTTTD | Abiraterone | 92 | 72 | 4.8 (4.2, 6.3) | |
| Docetaxel | 69 | 63 | 4.4 (3.7, 5.3) | |||
| OS | Abiraterone | 92 | 66 | 9.8 (6.7, 13.5) | ||
| Docetaxel | 69 | 58 | 7.0 (6.3, 9.3) | |||
| 1L NHT ≥ 6 months | TTTTD | Abiraterone | 198 | 154 | 6.8 (6.2, 8.0) | |
| Docetaxel | 63 | 54 | 5.3 (4.4, 8.2) | |||
| OS | Abiraterone | 198 | 116 | 14.0 (11.9, 17.6) | ||
| Docetaxel | 63 | 45 | 12.8 (10.9, 16.6) | |||
| 1L NHT < 12 months | TTTTD | Abiraterone | 184 | 140 | 5.7 (5.0, 7.0) | |
| Docetaxel | 107 | 96 | 4.5 (4.1, 5.3) | |||
| OS | Abiraterone | 184 | 125 | 10.4 (8.4, 12.0) | ||
| Docetaxel | 107 | 87 | 8.8 (7.7, 11.5) | |||
| 1L NHT ≥ 12 months | TTTTD | Abiraterone | 106 | 86 | 6.9 (5.9, 8.5) | |
| Docetaxel | 25 | 21 | 7.2 (4.9, 14.8) | |||
| OS | Abiraterone | 106 | 57 | 19.1 (14.7, 24.2) | ||
| Docetaxel | 25 | 16 | 15.1 (10.0, -) |